University of Iowa Research Foundation

Vanderbilt University

Mark E Anderson

Douglas R Spitz, Jr

Peter J Mohler

Jeffrey Robert Erickson

Joel N Kline

Aliasger Karimjee Salem

Frederick E Domann

Isabella M Grumbach

Mei-ling A Joiner

Duane D Hall

Amaraporn Wongrakpanich

Olha M Koval

Disclosed are compositions and methods for treating or preventing diseases or disorders associated with mitochondrial CaMKII activity.

Mitochondrial-targeted cationic nanoparticles comprising CaMKII inhibitors and uses thereof for treating and preventing diseases and disorders associated with CaMKII activity

Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.

Methods of detecting oxidized calcium/calmodulin dependent protein kinase II

Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II

Disclosed are methods of treating or preventing a pulmonary disease or disorder in a subject, the methods comprising administering an effective amount of an compound that inhibits Calmodulin Kinase II (CaMKII) activity, either directly or indirectly, thereby treating or preventing the pulmonary disease or disorder in the subject.

Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity

The present invention provides a method for treating structural heart disease in a subject, comprising administering an effective amount of an inhibitor of CaMKII to the subject, whereby the administration of the inhibitor treats the structural heart disease in the subject. Also provided are transgenic animal models for treating structural heart disease. Further provided is a means of screening for a compound that can treat structural heart disease.

Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease

Growing community of inventors

Iowa City, IA, United States of America

Mark E Anderson